HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

about

Methotrexate for treatment of vitiligo.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.

P2860

Q46836643-AF80AC6E-D58C-4349-BB72-9E1A4AACF613 Q50099588-2C338CEB-3821-4E0B-B517-9C5D14116135

P2860

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

Item

http://www.wikidata.org/entity/Q57638728

description

article

@en

im Mai 2017 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2017

@uk

name

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@en

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@nl

type

Item

label

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@en

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@nl

prefLabel

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@en

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@nl

P1476

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

@en

P2093

C Fleming

http://www.w3.org/2001/XMLSchema#string

J Berg

http://www.w3.org/2001/XMLSchema#string

J Foerster

http://www.w3.org/2001/XMLSchema#string

S Ogston

http://www.w3.org/2001/XMLSchema#string

V Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment.

Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.

Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.

Methotrexate for psoriasis in the era of biological therapy.

The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.

Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

P304

651-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CED.13100

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Colin Palmer

Jonathan West

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28512993

http://www.w3.org/2001/XMLSchema#string

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

about

P2860

P2860

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698